The IV Eurasian Rheumatology Congress attended by leading healthcare professionals from around the globe was held in Moscow on 26-28 September 2018.
The congress was organized by the All-Russian public organization “The Association of Rheumatologists of Russia” and the Federal State Budgetary Scientific Institution “V.A. Nasonova Research Institute of Rheumatology", on the occasion of its 60th anniversary.
During the event experts discussed upcoming medical products for treatment of various diseases. In particular, the methods of effective control of interleukin 6 (IL-6), dubbed by one of Russia’s most prominent specialists in rheumatology Dr. Yevgeniy Nasonov as “a key element in the inflammatory cascade responsible for many rheumatic disorders” were among the hottest topics.
About CREDO 1.
428 patients were enrolled in the trial at 43 research sites in Russia, Belarus and Bulgaria. The primary objective of this study is to evaluate the efficacy of OKZ in comparison with placebo in subjects with moderately or severely active rheumatoid arthritis inadequately controlled by methotrexate therapy. Patients were randomly assigned into 3 double-blind treatment groups: the first one is treated by 64 mg of OKZ administered subcutaneously once every 2 weeks, the second is subjected to the same dosage once every 4 weeks and the third receives placebo. The CREDO 1 study includes a 24 weeks double-blind treatment period. All patients, that completed CREDO 1 study, are eligible to enter CREDO 4 (a common open-label extension study evaluating long-term safety and tolerability of olokizumab) or undergo 20 more weeks of double-blind treatment within CREDO 1.
About CREDO Program
Clinical Rheumatoid Arthritis Development for olokizumab/CREDO is a clinical phase III trials program for Olokizumab that consist of the following studies:
• CREDO 1 (NCT02760368) is a multicenter international placebo-controlled trial that evaluates olokizumab versus placebo in RA patients from Russia / Belarus / Bulgaria with inadequate response to methotrexate.
• CREDO 2 (NCT02760407) is a multicenter international trial that evaluates olokizumab versus adalimumab and placebo in RA with inadequate response to methotrexate.
• CREDO 3 (NCT02760433) is a multicenter international trial that evaluates olokizumab versus placebo in RA patients with inadequate response to TNF-α therapies.
CREDO 4 is a common open-label extension study for patients who have completed CREDO 1, CREDO 2, or CREDO 3.
About Rheumatoid Arthritis
Rheumatoid arthritis is widespread worldwide. According to the Russian epidemiological study, over 700,000 people suffer from rheumatoid arthritis in Russia. This is a systemic connective tissue disease that typically affects small joints as an erosive-destructive polyarthritis with a complex autoimmune pathogenesis, leading to early disability and a shortened life expectancy of patients. The basis for treating rheumatoid arthritis is anti-inflammatory therapy, which includes the use of a wide range of drugs. In recent years, several innovative genetically engineered biological products have been specially developed to treat this disease. Olokizumab is one of these innovative drugs that blocks one of the important pro-inflammatory cytokines (IL-6).